Biogen Idec Inc (BIIB) 318.78 $BIIB Acorda 2Q Earnings &

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2015 at 2:48 AM

Biogen Idec Inc (BIIB) 318.78 $BIIB

Acorda 2Q Earnings & Revenues Top, Ampyra in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Jul 31, 2:43PM CDT
Acorda (ACOR) narrowed its 2015 guidance for Ampyra to $410 million - $420 million from $405 million - $420 million.
BIIB: 318.78 (+1.78), LGND: 108.26 (+0.48), AMAG: 63.90 (-0.87), ACOR: 34.36 (+0.13)

Price Isn't a Problem for Gilead Sciences
at The Street - Thu Jul 30, 10:00AM CDT
Drugmaker has one of the best showings of earnings season.
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), PFE: 36.06 (+0.33), MRK: 58.96 (+0.44), ABBV: 70.01 (-0.15), CELG: 131.25 (-0.63)

Attention New Biotech Investors: Biogen Inc's Recent Weakness Is Your Opportunity
Brian Feroldi, The Motley Fool - Motley Fool - Thu Jul 30, 8:38AM CDT
Investing in biotech stocks can be very intimidating for beginners, as many investors consider the word "biotech" to be synonymous with "risk". Press releases are filled with scientific jargon, many companies are losing money, and normal valuation...
BIIB: 318.78 (+1.78)

The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Jul 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA
BIIB: 318.78 (+1.78), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), REGN: 553.66 (+6.56), XOMA: 0.73 (-0.08)

Troubled Stocks Go From Worst to First
at The Street - Wed Jul 29, 3:05PM CDT
Oil- and commodity-related shares perform well.
BIIB: 318.78 (+1.78), ESPR: 62.00 (-2.25), VDSI: 20.39 (-0.78), FB: 94.01 (-1.20), BEAT: 12.23 (+0.54), DATA: 104.74 (-2.10)

Sorry, No Fed Effect Today
at The Street - Wed Jul 29, 1:22PM CDT
The market did its usual jig on the news and went along its merry way.
BIIB: 318.78 (+1.78), ESPR: 62.00 (-2.25), VDSI: 20.39 (-0.78), FB: 94.01 (-1.20), BEAT: 12.23 (+0.54), DATA: 104.74 (-2.10)

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 29, 10:48AM CDT
Last week saw several major biotech companies like Biogen (BIIB) and AbbVie (ABBV) reporting second quarter results.
BIIB: 318.78 (+1.78), VRTX: 135.00 (-0.46), ALXN: 197.44 (-1.85), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), REGN: 553.66 (+6.56), XOMA: 0.73 (-0.08)

Make Sure You Don't Get Caught in a Breakdown
at The Street - Wed Jul 29, 9:11AM CDT
Nothing much sticks out to the upside right now.
BIIB: 318.78 (+1.78), ESPR: 62.00 (-2.25), VDSI: 20.39 (-0.78), FB: 94.01 (-1.20), BEAT: 12.23 (+0.54), DATA: 104.74 (-2.10)

Stock Market News for July 29, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 9:10AM CDT
Benchmarks gained over 1% on Tuesday as investors focused on upbeat earnings results, ignoring the selloff in China’s stock market
BIIB: 318.78 (+1.78), F: 14.83 (-0.27), RIG: 13.26 (-0.69), GILD: 117.86 (-0.04), PFE: 36.06 (+0.33), COP: 50.34 (-1.73), XOM: 79.21 (-3.80), AMGN: 176.59 (+4.90), DD: 55.76 (+0.17), CVX: 88.48 (-4.55), SLB: 82.82 (-0.70), UPS: 102.36 (+0.96), CELG: 131.25 (-0.63)

5 Stocks Insiders Love Right Now
at The Street - Wed Jul 29, 7:14AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
RDUS: 78.32 (+3.08), ZINC: 8.28 (+0.21), BIIB: 318.78 (+1.78), MJN: 88.39 (-1.09), DPZ: 113.84 (unch)

Biogen Stock Remains Deeply Oversold
at The Street - Wed Jul 29, 5:00AM CDT
Three ways to profit after last Friday's crazy freefall.
BIIB: 318.78 (+1.78)

Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good)
at The Street - Tue Jul 28, 3:15PM CDT
Gilead Sciences will not be blamed for a cooling of the biotech bull market, if any such thing exists.
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04)

Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 331.15 (+2.28), BIIB: 318.78 (+1.78), SHPG: 266.81 (+4.29), MYL: 55.99 (-0.36), AMGN: 176.59 (+4.90), ABBV: 70.01 (-0.15), TEVA: 69.02 (-0.05)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Biogen, Inc.
PR Newswire - Tue Jul 28, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Biogen, Inc. ("Biogen" or the "Company"

(NasdaqGS: BIIB -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
BIIB: 318.78 (+1.78)

The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 165.83 (+6.66), BIIB: 318.78 (+1.78), LGND: 108.26 (+0.48), REGN: 553.66 (+6.56), EXEL: 5.73 (+0.19)

Watching Twitter for Moves at Teva and Biogen
at The Street - Tue Jul 28, 7:28AM CDT
Twitter sentiment predicts the big moves in two healthcare stocks-NYMX and BIIB.
BIIB: 318.78 (+1.78), TEVA: 69.02 (-0.05)

3 Big Biotech Buybacks That Investors Should Love
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jul 28, 6:03AM CDT
Source: Images Of Money/Flickr Creative Commons. Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found...
BIIB: 318.78 (+1.78), GILD: 117.86 (-0.04), CELG: 131.25 (-0.63)

Biogen & the Parkinson's Institute and Clinical Center reports strategic alliance to form novel tools and programmes to accelerate research and the development of new treatments in Parkinson's disease
M2 - Tue Jul 28, 5:33AM CDT
Biotechnology company Biogen (NasdaqGS:BIIB) revealed on Monday the establishment of a strategic alliance with the Parkinson's Institute and Clinical Center, to enhance the understanding of the underlying biology of Parkinson's disease (PD) and the creation of novel tools and programmes that could accelerate research and the development of new PD treatments.
BIIB: 318.78 (+1.78)

'Mad Money' Lightning Round: Sell, Sell, Sell SanDisk
at The Street - Tue Jul 28, 5:00AM CDT
Cramer thinks Cerus is a nice speculative stock, says to wait on ConocoPhillips and to buy 3M at $142.
CERS: 5.43 (+0.09), MMM: 151.34 (-0.23), BIIB: 318.78 (+1.78), ISIS: 54.93 (+1.76), MDSO: 53.80 (-0.22), COP: 50.34 (-1.73), SNDK: 60.29 (-0.26)

Jim Cramer's 'Mad Money' Recap: Beware the Market's FANGs
at The Street - Mon Jul 27, 7:16PM CDT
Cramer says this is the thinnest market we've seen in ages, and that's not good.
CERS: 5.43 (+0.09), MMM: 151.34 (-0.23), AMZN: 536.15 (-0.61), BIIB: 318.78 (+1.78), MDLZ: 45.13 (-0.14), EA: 71.55 (-0.75), SNA: 164.80 (+0.42), NKE: 115.22 (+0.21), MDSO: 53.80 (-0.22), FB: 94.01 (-1.20), FCX: 11.75 (-0.09), COP: 50.34 (-1.73), DIS: 120.00 (-0.03), NFLX: 114.31 (+2.75), ISIS: 54.93 (+1.76), QLIK: 40.46 (-0.04), KHC: 79.47 (+0.26), GOOGL: 657.50 (-7.06), ULTA: 166.03 (-0.79), CMCSA: 62.41 (+0.05), GIS: 58.21 (-0.05), SNDK: 60.29 (-0.26)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

EFICYENT Ventures to Connect at Singapore FinTech Fest

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...